drugset / Trial / NCT04663035

Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC

NCT04663035 ↗

Phase 2 Unknown 120 enrolled Ming Zhao
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, controlled, phase 2 study to assess the efficacy and safety of ablation followed by tislelizumab versus ablation alone in patients with early recurrent hepatocellular carcinoma.

Timeline

Start
2020-12-21
Primary completion
2023-12-18
Completion
2025-12-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous